Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series C brings $37mm to Concert Pharmaceuticals

Executive Summary

Concert Pharmaceuticals (deuterium-based drug discovery technology) raised $37mm through its Series C round. An undisclosed public institutional investor led, and was joined by new buyers Adage Capital Management, SR One, Mediphase Venture Partners, and Westfield Capital Management. Existing backers Three Arch Partners, TVM Capital, Skyline Ventures, Brookside Capital Partners, Flagship Ventures, Greylock Partners, New Leaf Venture Partners, and QVT Fund also participated.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies